Biodesix, Inc. entered into a Second Amendment to its $30 million 2021 Term Loan on December 31, 2021, which includes modifications to certain restrictive financial covenants to provide the Company additional financial flexibility over the near term to advance its strategic growth objectives. The key terms under the Second Amendment to $30 million 2021 Term Loan include the following: Consent for a $4.6 millionJanuary 2022 milestone payment under the Integrated Diagnostics APA; Repayment of $20 million in outstanding principal on December 31, 2021; and Waiver and elimination of $600,000 prepayment fee on the $20 million Term Loan repayment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +2.91% |
|
+9.26% | -3.80% |
07-05 | Certain Common Stock of Biodesix, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2024. | CI |
05-21 | Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.80% | 250M | |
-18.17% | 8.55B | |
+87.40% | 4.63B | |
+16.31% | 2.98B | |
-3.15% | 2.65B | |
-2.10% | 1.89B | |
-53.27% | 1.81B | |
-12.97% | 1.56B | |
+21.59% | 1.27B | |
-47.96% | 1.07B |
- Stock Market
- Equities
- BDSX Stock
- News Biodesix, Inc.
- Biodesix, Inc. Announces Second Amendment to $30 Million Term Loan Provides Additional Financial Flexibility for Growth